Delivery Order SPE2DR25D3301-SPE2DR26F18XD
- Not listed
- The Defense Logistics Agency awarded a $4,429.68 delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed-price, competitively awarded contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the company's headquarters location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,112.80 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on December 8, 2025, with a completion date of December 9, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract is part of AmerisourceBergen's...
- The Defense Logistics Agency awarded a $4,839.72 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is expected to be completed by September 15, 2025, and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a delivery order valued at $8,640.49 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 ml pen injections on September 23, 2025, with completion scheduled for September 24, 2025. This competitive, non-set-aside delivery order utilizes firm fixed pricing and represents a routine pharmaceutical procurement for federal medical supply needs. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $4,451.71 delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of November 7, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $5,144.31. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside, competitively awarded procurement. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $10,186.58 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed price, non-set-aside delivery order was issued on August 27, 2025, with an ultimate completion date of August 28, 2025. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 19, 2025. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a small transaction within the...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F18XDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,463.35 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections on December 3, 2025, with a completion date of December 4, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services through AmerisourceBergen's larger contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle valued through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare systems globally. AmerisourceBergen serves as a critical vendor within the Defense Logistics Agency's medical supply chain, fulfilling federal procurement requirements for medications across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The contract involves no set-aside designation and demonstrates the company's capability to meet federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 12/2/25 |